ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1353

Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage

Laura Coates1, Désirée van der Heijde2, Lars Erik Kristensen3, William Tillett4, Jason Eells5, Tommi Nurminen6 and Atul Deodhar7, 1University of Oxford, Oxford, United Kingdom, 2Leiden University Medical Center, Leiden, Netherlands, 3The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, 4Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, 5UCB Pharma, Slough, United Kingdom, 6UCB Pharma, Monheim am Rhein, Germany, 7Oregon Health & Science University, Portland, OR

Meeting: ACR Convergence 2020

Keywords: Anti-TNF Drugs, Biologicals, Disease Activity, Patient reported outcomes, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we evaluate whether pre-existing structural damage in patients with active PsA limits functional improvements from treatment with certolizumab pegol (CZP) over 4 years. CZP is an Fc-free, PEGylated, tumor necrosis factor inhibitor that has shown long-term efficacy and safety in patients with PsA.3

Methods: Patients enrolled in RAPID-PsA (NCT01087788) with active PsA (≥3 tender joints; ≥3 swollen joints; ESR ≥28 mm/hour and/or CRP >upper limit of normal) who had failed treatment with ≥1 DMARD were randomized 1:1:1 to CZP 200 mg every 2 weeks (wks; Q2W), CZP 400 mg every 4 wks (Q4W) or placebo. Both CZP treatment arms received a loading dose of CZP 400 mg at Wks 0, 2, and 4, followed by the randomized dose regimen to Wk 216.3 Current analyses are based on data pooled across active treatment arms. Radiographs taken at baseline and Wks 12, 24, 48, 96, 168 and 216/withdrawal were read using the van der Heijde modified Total Sharp Score (mTSS) for PsA (scores based on average of two readers). Patients were grouped according to baseline mTSS quartiles (Q1–Q4). Disease activity was assessed using Disease Activity Index for Psoriatic Arthritis (DAPSA; high disease activity [HDA]: >28; moderate [MoDA]: >14–≤28; low [LDA]: >4–≤14; remission: ≤4). Physical function was assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI; ≤0.5 defined as no adverse impact on physical function).4 The association of HAQ-DI, both change from baseline and achievement of ≤0.5, and concurrent DAPSA status was compared between the baseline mTSS groups using descriptive statistics.

Results: Of 409 patients randomized, 407 were assessed for mTSS. As expected, at baseline, HAQ-DI scores were numerically higher in patients in mTSS Q3 and Q4 than Q1 (Table). With CZP treatment, across all mTSS quartiles, the proportion of patients in DAPSA remission increased over time (Figure 1). Across all mTSS quartiles (Q1–Q4), at least 80% of patients who achieved DAPSA remission also achieved HAQ-DI ≤0.5 (no adverse impact on physical function) at Wk 24 of CZP treatment. Over 80% of patients in mTSS Q1 who achieved either DAPSA remission or LDA also achieved HAQ-DI ≤0.5 at Wk 24. However, for mTSS Q2–Q4, >90% of patients in DAPSA remission achieved HAQ-DI ≤0.5 as compared with only ~30–50% of patients with DAPSA LDA (Figure 2).

Conclusion: These data indicate that patients achieving a high level of disease control (DAPSA remission) over 4 years of treatment with CZP are likely to achieve a normative state in terms of physical function, regardless of pre-existing radiographic damage. However, a state of DAPSA LDA may not result in normalization of function in patients with pre-existing radiographic damage. This supports the rationale of aiming for remission in PsA.

References

1. Bond SJ. ARD 2007;66:370–6; 2. Torre Alonso JC. Rheumatology 1991;30:245–50; 3. van der Heijde D. RMD Open 2018;4:e000582; 4. Strand V. ART 2018;20:269.


Disclosure: L. Coates, AbbVie, 2, 5, 8, Celgene, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Amgen Inc., 5, 8, Gilead, 5, 8, Janssen, 5, 8, UCB Pharma, 5, 8, Eli Lilly, 2, 5, 8, Biogen, 8, Medac, 8, Boehringer Ingelheim, 5, MSD, 5; D. van der Heijde, AbbVie, 5, Bristol-Myers Squibb, 5, Cyxone, 5, Galapagos NV, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Eli Lilly, 5, Novartis, 5, Pfizer, 5, UCB Pharma, 5, Amgen Inc., 5, Astellas, 5, AstraZeneca, 5, Boehringer Ingelheim, 5, Celgene, 5, Daiichi-Sankyo, 5, Janssen, 5, Merck, 5, Regeneron, 5, Roche, 5, Sanofi, 5, Takeda, 5, Imaging Rheumatology bv, 3, Eisai, 5; L. Kristensen, AbbVie, 2, 8, Amgen Inc., 2, 8, Biogen, 2, 8, BMS, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Novartis, 2, 8, Pfizer, 2, 8, UCB Pharma, 2, 8, Sanofi, 2, 5, 8; W. Tillett, AbbVie, 5, 8, Amgen, 5, 8, Eli Lilly, 5, 8, Janssen, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, UCB Pharma, 5, 8; J. Eells, UCB Pharma, 1, 3; T. Nurminen, UCB Pharma, 3; A. Deodhar, AbbVie, 2, 5, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Novartis, 2, 5, Janssen, 5, Pfizer, 2, 5, Boehringer Ingelheim, 5, UCB Pharma, 2, 5, Amgen Inc., 5, Celgene, 5, Galapagos, 5, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Coates L, van der Heijde D, Kristensen L, Tillett W, Eells J, Nurminen T, Deodhar A. Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/achievement-of-remission-is-associated-with-improvement-in-functionality-in-certolizumab-pegol-treated-patients-with-psoriatic-arthritis-irrespective-of-pre-existing-radiographic-structural-damage/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/achievement-of-remission-is-associated-with-improvement-in-functionality-in-certolizumab-pegol-treated-patients-with-psoriatic-arthritis-irrespective-of-pre-existing-radiographic-structural-damage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology